V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240008522 | 240010877 | 1.64 | 49.4 | Curative (C) | 2013-04-14 | 2013-05-17 | Bortezomib | 02 | N | 240014317 | IDELALISIB + RITUXIMAB |
| 240008523 | 240005207 | 1.51 | 57.5 | Curative (C) | 2017-01-30 | 2017-01-30 | Gemcitabine 1000mg/m2 D1 8 15 | N | N | 240014534 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008524 | 240010878 | 1.89 | null | Palliative (P) | 2016-05-01 | 2016-05-14 | Cyclophosphamide + Dex + Rituximab | Y | N | 240014544 | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE |
| 240008525 | 240005208 | 1.71 | 54.1 | null | 2017-03-08 | 2017-03-08 | Cisplatin + Etoposide (3 day) | N | N | 240014568 | R-EPOCH |
| 240008526 | 240010879 | 0 | 62.9 | Curative (C) | 2015-11-05 | 2015-11-06 | R-CHOEP | 2 | N | 240014572 | FCR |
| 240008527 | 240010879 | 1.58 | 78 | Neo-adjuvant (N) | 2015-10-27 | 2015-10-28 | Cisplatin + Etoposide (3 day) | 02 | N | 240014572 | GEMCARBO |
| 240008528 | 240005209 | 1.61 | 109 | Adjuvant (A) | 2018-02-02 | 2018-03-01 | CARBOPLATIN + FLUOROURACIL | N | Y | 240014670 | BORTEZOMIB + THALIDOMIDE |
| 240008529 | 240005210 | 1.74 | 75 | Adjuvant (A) | 2016-08-24 | 2016-08-29 | CISPLATIN + FLUOROURACIL | N | N | 240014722 | CARBOPLATIN + TOPOTECAN |
| 240008530 | 240005211 | 1.53 | 53 | Curative (C) | null | 2017-05-23 | Palbociclib | null | null | 240014781 | CYTARABINE HD + METHOTREXATE HD |
| 240008531 | 240005211 | null | 62 | null | 2015-10-19 | 2015-10-19 | CARBOPLATIN + PACLITAXEL + RT | Y | N | 240014781 | CISPLATIN + ETOPOSIDE + RT |
| 240008532 | 240005212 | 1.55 | 60.8 | Curative (C) | 2014-05-12 | 2014-05-13 | Cisplatin + Etoposide po&iv 3 day | Y | N | 240014851 | CHOEP |
| 240008533 | 240005212 | 1.6 | 45.5 | Curative (C) | 2017-09-26 | 2017-10-07 | CISPLATIN + FLUOROURACIL | 2 | N | 240014851 | RUXOLITINIB |
| 240008534 | 240005213 | 1.85 | 58 | Curative (C) | 2016-07-11 | 2016-07-17 | Capecitabine + Oxaliplatin 21day | N | N | 240014900 | AML19 TRIAL |
| 240008535 | 240005214 | 1.53 | 86 | Curative (C) | 2018-05-18 | 2018-05-18 | CISPLATIN + FLUOROURACIL + RT | N | N | 240015005 | CODOX M |
| 240008536 | 240005214 | 1.67 | 0 | Not known (9) | 2016-03-12 | 2016-03-29 | Cisplatin + Etoposide (3 day) | N | N | 240015005 | FLUDARABINE |
| 240008537 | 240005214 | 1.7 | 70.2 | Adjuvant (A) | 2019-02-08 | 2019-02-09 | BEVACIZUMAB + CISPLATIN + PACLITAXEL | 02 | Y | 240015005 | FLUOROURACIL + MITOMYCIN + RT |
| 240008538 | 240005215 | 1.64 | 69 | Palliative (P) | 2018-10-28 | 2018-10-31 | CYCLO + RITUXIMAB + VINCRISTINE | 2 | N | 240015118 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE + RITUXIMAB |
| 240008539 | 240005216 | 0 | 65.7 | Palliative (P) | 2018-02-23 | 2018-02-23 | Cisplatin +Fluorouracil (2 wk) | null | N | 240015148 | GEMCARBO |
| 240008540 | 240005216 | 1.47 | 58 | Curative (C) | 2016-04-04 | 2016-04-11 | AML17 TRIAL | 02 | N | 240015148 | CISPLATIN + ETOPOSIDE |
| 240008541 | 240005216 | 1.57 | 95 | Curative (C) | 2016-02-22 | 2016-02-22 | ABVD | 2 | N | 240015148 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB |
| 240008542 | 240005217 | null | 14 | Disease modification (D) | 2016-08-15 | 2016-08-17 | ABVD | N | N | 240015306 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 240008543 | 240005218 | null | 50.7 | Palliative (P) | null | 2013-06-03 | Paclitaxel 7 day | null | null | 240015312 | CYTARABINE |
| 240008544 | 240005218 | 1.6 | 44.9 | Palliative (P) | 2017-12-05 | 2017-12-05 | FLUOROURACIL | N | N | 240015312 | BEVACIZUMAB + CARBO + DOCETAXEL |
| 240008545 | 240005219 | 1.73 | 75 | Palliative (P) | 2016-09-17 | 2016-09-20 | GEMCARBO | 2 | N | 240015434 | MATRIX TRIAL |
| 240008546 | 240010885 | 1.72 | 99.2 | Palliative (P) | 2018-06-14 | 2018-06-16 | Cisplatin + Pemetrexed | Y | Y | 240015505 | CISPLATIN + ETOPOSIDE |
| 240008547 | 240005220 | null | 76 | Curative (C) | 2015-06-26 | 2015-07-08 | CYCLOPHOSPHAMIDE + GEMCITABINE + VINCRISTINE | N | N | 240015521 | R-EPOCH |
| 240008548 | 240005220 | 1.47 | 69.7 | null | 2015-06-25 | 2015-06-25 | DHAP - R | null | N | 240015521 | CISPLATIN + FLUOROURACIL + RT |
| 240008549 | 240005220 | 1.64 | 68 | Curative (C) | 2014-08-22 | 2016-08-25 | Methotrexate intrathecal | Y | null | 240015521 | BEVACIZUMAB + CISPLATIN + PACLITAXEL |
| 240008550 | 240014972 | 1.76 | 70.2 | Curative (C) | 2016-02-12 | 2016-02-20 | CYCLOPHOSPHAMIDE + RITUXIMAB | N | N | 240015633 | CVP |
| 240008551 | 240014972 | 1.6 | 64.4 | Curative (C) | 2017-10-07 | 2017-10-13 | CARBOPLATIN + GEMCITABINE | 2 | N | 240015633 | BEVACIZUMAB + CISPLATIN + PACLITAXEL |
| 240008552 | 240016017 | null | null | Radical (R) | 2017-09-18 | 2017-09-18 | Trastuzumab Subcutaneous | N | null | 240015692 | R-CHOEP |
| 240008553 | 240005221 | 1.6 | 72.6 | Neo-adjuvant (N) | 2017-11-11 | 2017-11-30 | FLAG + Idarubicin | N | N | 240015839 | FEC + DOCETAXEL |
| 240008554 | 240010887 | 1.55 | 66 | Palliative (P) | 2018-09-13 | 2018-09-13 | Cisplatin + Etoposide (3 day) | 2 | N | 240015857 | R-EPOCH |
| 240008555 | 240013630 | 1.69 | 80.8 | Disease modification (D) | null | 2016-10-29 | CARBOPLATIN + IFOSFAMIDE | N | N | 240015871 | BEVACIZUMAB |
| 240008556 | 240013630 | 1.48 | 65.4 | null | 2017-11-23 | 2017-11-30 | Paclitaxel 7 day | 2 | N | 240015871 | TOPOTECAN |
| 240008557 | 240005222 | 1.74 | 109 | Palliative (P) | 2017-05-23 | 2017-05-24 | CVP | N | N | 240016012 | METHOTREXATE INTRATHECAL |
| 240008558 | 240005222 | 1.8 | null | Curative (C) | 2014-11-13 | 2014-11-29 | Cytarabine HD + Methotrexate HD | N | N | 240016012 | FCR |
| 240008559 | 240005223 | 1.83 | 98.7 | Palliative (P) | 2017-11-30 | 2017-12-20 | MidAC | 2 | N | 240016051 | DHAP - R |
| 240008560 | 240005224 | 1.59 | 43.6 | Curative (C) | 2015-04-21 | 2015-05-05 | Mitoxantrone | N | N | 240016070 | CARBOPLATIN + RT |
| 240008561 | 240005224 | 1.56 | null | Palliative (P) | 2017-05-20 | 2017-05-20 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | N | 240016070 | ICON TRIAL |
| 240008562 | 240005224 | null | 86 | null | 2018-02-09 | 2018-02-10 | ESHAP R | N | N | 240016070 | ABVD |
| 240008563 | 240005225 | 1.76 | 76 | Curative (C) | 2014-09-04 | 2014-09-27 | CISPLATIN + FLUOROURACIL | N | null | 240016204 | TRASTUZUMAB |
| 240008564 | 240005226 | 1.65 | 0 | Curative (C) | 2016-09-16 | 2016-09-16 | Cisplatin + Topotecan | N | Y | 240016277 | MPV |
| 240008565 | 240005226 | 1.7 | 90.3 | Disease modification (D) | 2016-05-16 | 2016-05-16 | RUXOLITINIB | 02 | N | 240016277 | CARBOPLATIN + PACLITAXEL + RT |
| 240008566 | 240005227 | 1.64 | 64.4 | Palliative (P) | 2016-10-27 | 2016-10-31 | CARBOPLATIN + FLUOROURACIL | 02 | N | 240016330 | BLEOMYCIN + CISPLATIN + MTOMYCIN |
| 240008567 | 240005228 | 0 | null | Disease modification (D) | 2016-08-31 | 2016-08-31 | AML Int Guide ADE 10+3+5 (1) | 2 | N | 240016360 | CYCLOPHOSPHAMIDE |
| 240008568 | 240005229 | 1.55 | 79.2 | Curative (C) | 2017-11-06 | 2017-11-22 | BEVACIZUMAB + CISPLATIN + PACLITAXEL | 2 | N | 240016409 | CISPLATIN + ETOPOSIDE |
| 240008569 | 240005230 | 1.65 | 70.1 | Disease modification (D) | 2014-04-22 | 2014-04-30 | VINCRISTINE | N | N | 240016423 | GEMCARBO |
| 240008570 | 240005231 | null | 85.6 | Palliative (P) | 2018-08-07 | 2018-08-11 | Cyclophosphamide + Dex + Rituximab | N | N | 240016492 | MPV |
| 240008571 | 240005232 | 1.6 | 100.3 | Adjuvant (A) | 2015-01-28 | 2015-01-28 | CHOEP | null | N | 240016504 | ICE |